journal
MENU ▼
Read by QxMD icon Read
search

Clinical Colorectal Cancer

journal
https://www.readbyqxmd.com/read/29233603/individual-susceptibility-analysis-using-patient-derived-slice-cultures-of-colorectal-carcinoma
#1
Rasmus Sönnichsen, Laura Hennig, Vera Blaschke, Karsten Winter, Justus Körfer, Susann Hähnel, Astrid Monecke, Christian Wittekind, Boris Jansen-Winkeln, René Thieme, Ines Gockel, Kerstin Grosser, Arved Weimann, Christoph Kubick, Volker Wiechmann, Achim Aigner, Ingo Bechmann, Florian Lordick, Sonja Kallendrusch
BACKGROUND: Nonresponse to chemotherapy in colorectal carcinoma (CRC) is still a clinical problem. For most established treatment regimens, no predictive biomarkers are available. Patient-derived tumor slice culture may be a promising ex vivo technology to assess the drug susceptibility in individual tumors. METHODS: Patient-derived slice cultures of CRC specimens were prepared according to a standardized protocol and treated with different concentrations of 5-fluorouracil (5-FU) and an adapted FOLFOX regimen (5-FU and oxaliplatin) to investigate histologic response...
November 21, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29223361/evidence-suggests-sphingosine-1-phosphate-might-be-actively-generated-degraded-and-transported-to-extracellular-spaces-with-increased-s1p2-and-s1p3-expression-in-colon%C3%A2-cancer
#2
Baasanjav Uranbileg, Takeshi Nishikawa, Hitoshi Ikeda, Makoto Kurano, Masaya Sato, Daisuke Saigusa, Junken Aoki, Toshiaki Watanabe, Yutaka Yatomi
BACKGROUND: A pivotal role of sphingosine 1-phosphate (S1P) in cancer has been suggested based on the ceramide-S1P rheostat theory that the intracellular balance between prosurvival S1P and proapoptotic ceramide determines cell fate. Upregulation of S1P-generating sphingosine kinases (SKs) and downregulation of S1P-degrading S1P lyase (SPL) might increase intracellular S1P levels to exert a prosurvival effect in cancer in general, such as colon cancer. However, we recently observed a distinct S1P metabolism in hepatocellular carcinoma tissues that increased SPL mRNA levels with reduced S1P levels...
November 21, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29221688/primary-tumor-location-and-survival-in-the-general-population-with-metastatic-colorectal-cancer
#3
Shahid Ahmed, Punam Pahwa, Duc Le, Haji Chalchal, Selliah Chandra-Kanthan, Nayyer Iqbal, Anthony Fields
BACKGROUND: Recent evidence from clinical trials suggests that primary tumor location in patients with metastatic colorectal cancer correlates with differential outcomes, and patients with tumors originating in the right side of the colon have inferior survival. We conducted a large population-based cohort study using individual patient data to confirm the prognostic importance of primary tumor location in the general population with metastatic colorectal cancer. METHODS: A cohort of 1947 patients who were diagnosed with metastatic colorectal cancer from 1992 to 2010 was studied...
November 21, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29221687/leptomeningeal-carcinomatosis-in-colorectal-cancer-the-mayo-clinic-experience
#4
Gretchen Taylor, Nina Karlin, Thorvardur R Halfdanarson, Kyle Coppola, Axel Grothey
BACKGROUND: Leptomeningeal metastasis (LM) is an uncommon form of metastatic disease in many cancers. There remains a paucity of literature with regard to the course and management of LM in colorectal cancers (CRCs). The aim of this study was to estimate the incidence of LM in patients with CRC seen at our institution over a 15-year period, and to describe the clinical course and outcome of these cases. METHODS: LM in CRC primary cases between 2000 and 2014 were identified in the Mayo Clinic databases...
November 21, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29208445/optimal-interval-for-18f-fdg-pet-after-chemoradiotherapy-for-rectal-cancer
#5
Kazushige Kawai, Hiroaki Nozawa, Keisuke Hata, Toshiaki Tanaka, Takeshi Nishikawa, Koji Oba, Toshiaki Watanabe
INTRODUCTION: Although 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) has been increasingly used to evaluate the response to preoperative chemoradiotherapy (CRT) in patients with rectal cancer, the optimal intervals between completion of CRT, PET, and surgery have not been fully investigated. PATIENTS AND METHODS: A total of 148 consecutive patients with rectal adenocarcinoma who received CRT followed by FDG-PET and radical surgery were retrospectively analyzed...
November 21, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29174481/a-comparison-of-regorafenib-and-tas-102-for-metastatic-colorectal-cancer-a-systematic-review-and-network-meta-analysis
#6
Ana B K Abrahao, Yoo-Joung Ko, Scott Berry, Kelvin K W Chan
BACKGROUND: Regorafenib and TAS-102 have shown to be superior to placebo in refractory metastatic colorectal cancer. However, no studies have directly compared both drugs. Giving the lack of standard options in this scenario, a systematic review to compare the efficacy and safety of regorafenib and TAS-102 was performed. MATERIALS AND METHODS: A systematic review using the PubMed, Medline, Embase, Scopus, and Cochrane databases to identify published and unpublished studies up to November 2015 for randomized controlled trials for patients with metastatic colorectal cancer, involving regorafenib or TAS-102, was performed...
November 21, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29157662/evaluation-of-guideline-adherence-in-colorectal-cancer-treatment-in-the-netherlands-a-survey-among-medical-oncologists-by-the-dutch-colorectal-cancer-group
#7
Lotte Keikes, Martijn G H van Oijen, Valery E P P Lemmens, Miriam Koopman, Cornelis J A Punt
BACKGROUND: Clinical guidelines are generated to preserve high-quality evidence-based care. Data on the implementation of guidelines into clinical practice are scarce, despite that guideline adherence prevents over- and undertreatment and correlates with survival. Therefore, we investigated guideline adherence for the systemic treatment in high-risk stage II and stage III colon cancer and metastatic colorectal cancer. PATIENTS AND METHODS: In all Dutch hospitals (n = 88) 1 medical oncologist involved in colorectal cancer care was approached to participate...
November 17, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29153429/optimal-interval-to-surgery-after-neoadjuvant-chemoradiotherapy-in-rectal-cancer-a%C3%A2-systematic-review-and-meta-analysis
#8
REVIEW
Donglin Du, Zhourong Su, Dan Wang, Wenwen Liu, Zhengqiang Wei
This study aimed to evaluate the influence of a waiting interval of ≥ 8 weeks between the end of preoperative neoadjuvant chemoradiotherapy (nCRT) and surgery on the outcomes of patients with locally advanced rectal cancer. We conducted a comprehensive literature review of retrospective and prospective studies from PubMed, Embase, and Cochrane Library databases to investigate the length of the preoperative nCRT-surgery waiting interval and outcomes in patients with locally advanced rectal cancer. The primary outcome measure was pathologic complete response (pCR) rate...
November 15, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29195807/parallel-evaluation-of-circulating-tumor-dna-and-circulating-tumor-cells-in-metastatic-colorectal-cancer
#9
Giovanni Germano, Gianluca Mauri, Giulia Siravegna, Caroline Dive, Jackie Pierce, Federica Di Nicolantonio, Maurizio D'Incalci, Alberto Bardelli, Salvatore Siena, Andrea Sartore-Bianchi
BACKGROUND: Tissue biopsy is the gold standard for tumor genotyping, but it is an invasive procedure providing a single snapshot into tumor heterogeneity. Liquid biopsy approaches, encompassing the analysis of circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs), have been proposed as an alternative, with the potential of providing a comprehensive portrait of the tumor molecular landscape. In metastatic colorectal cancer (mCRC), both CTCs and ctDNA analysis have been investigated, but comparative analyses are limited...
November 1, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29223362/autophagy-inhibition-in-pancreatic-adenocarcinoma
#10
REVIEW
Brian A Boone, Herbert J Zeh, Nathan Bahary
Although some progress has been made in recent years with the development of more effective chemotherapy regimens, new treatment approaches are needed to improve outcomes for patients with pancreatic adenocarcinoma. The cellular process of autophagy, a cell survival mechanism that allows cancer cells to survive the hazardous conditions of the tumor microenvironment and treatment, has emerged as a viable target in pancreatic cancer. We review the mechanism of autophagy, its role in pancreatic carcinogenesis, the preclinical and clinical evidence supporting targeting autophagy in patients with pancreatic adenocarcinoma, and areas of future investigation that hold promise for improving this treatment approach...
October 28, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29162332/integrating-downstaging-in-the-risk-assessment-of-patients-with-locally-advanced-rectal-cancer-treated-with-neoadjuvant-chemoradiotherapy-validation-of-valentini-s-nomograms-and-the-neoadjuvant-rectal-score
#11
Susana Roselló, Matteo Frasson, Eduardo García-Granero, Desamparados Roda, Esther Jordá, Samuel Navarro, Salvador Campos, Pedro Esclápez, Stephanie García-Botello, Blas Flor, Alejandro Espí, Carlotta Masciocchi, Vincenzo Valentini, Andrés Cervantes
BACKGROUND: Adjuvant chemotherapy is controversial in patients with locally advanced rectal cancer after preoperative chemoradiation. Valentini et al developed 3 nomograms (VN) to predict outcomes in these patients. The neoadjuvant rectal score (NAR) was developed after VN to predict survival. We aimed to validate these tools in a retrospective cohort at an academic institution. PATIENTS AND METHODS: VN and the NAR were applied to 158 consecutive patients with locally advanced rectal cancer treated with chemoradiation followed by surgery...
October 28, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29153431/monoclonal-antibodies-targeting-the-il-17-il-17ra-axis-an-opportunity-to-improve-the-efficiency-of-anti-vegf-therapy-in-fighting-metastatic-colorectal-cancer
#12
REVIEW
Sajida Ibrahim, Alban Girault, Marc Ohresser, Emilie Lereclus, Gilles Paintaud, Thierry Lecomte, William Raoul
Colorectal cancer is a major problem for public health worldwide because of its frequency and its severity. Many efforts have been carried to target the vascular endothelial growth factor (VEGF) pathway, one of the main promoters of pathological angiogenesis. Therapeutic monoclonal antibodies against VEGF have emerged as essential biopharmaceuticals for the advanced stages of the disease, in association with appropriate backbone chemotherapy. Unfortunately, after an initial benefit for the patients, resistance invariably develops...
October 28, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29233486/cetuximab-combined-with-induction-oxaliplatin-and-capecitabine-followed-by-neoadjuvant-chemoradiation-for-locally-advanced-rectal-cancer-swog-0713
#13
Cynthia Gail Leichman, Shannon L McDonough, Stephen R Smalley, Kevin G Billingsley, Heinz-Josef Lenz, Matthew A Beldner, Aram F Hezel, Mario R Velasco, Katherine A Guthrie, Charles D Blanke, Howard S Hochster
BACKGROUND: Neoadjuvant chemoradiation (NCRT) is standard treatment for locally advanced rectal cancer. Pathologic complete response (pCR) has associated with improved survival. In modern phase III trials of NCRT, pCR ranges from 10% to 20%. Cetuximab improves response in KRAS (KRAS proto-oncogene) wild type (wt) metastatic colorectal cancer. S0713 was designed to assess improvement in pCR with additional use of cetuximab with induction chemotherapy and NCRT for locally advanced, KRAS-wt rectal cancer...
October 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29169975/an-unusual-case-of-colorectal-adenocarcinoma-presenting-as-an-anterior-mediastinal-mass
#14
Joshua L Rodríguez-López, Alia M Toro-Bahamonde, Roberto J Santiago-Méndez, Iván F González-Cancel, Héctor A Vélez-Cortés
No abstract text is available yet for this article.
October 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29153430/real-world-effect-of-maintenance-and-intermittent-chemotherapy-on-survival-in-metastatic-colorectal-cancer
#15
Jonathan M Loree, Sean K Tan, Laurence M Lafond, Caroline H Speers, Hagen F Kennecke, Winson Y Cheung
BACKGROUND: With improved survival and longer duration of treatment, clinicians managing metastatic colorectal cancer (mCRC) increasingly consider intermittent (IC) or maintenance chemotherapy (MC), but the effect of these treatment modifications on real-world outcomes is unclear. PATIENTS AND METHODS: Using a population-based cohort of mCRC patients who received combination chemotherapy, we aimed to describe the use of IC/MC and their effect on overall survival (OS)...
October 23, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29128266/molecular-profiling-of-patients-with-advanced-colorectal-cancer-princess-margaret-cancer-centre-experience
#16
Joanne W Chiu, Monika K Krzyzanowska, Stefano Serra, Jennifer J Knox, Neesha C Dhani, Helen Mackay, David Hedley, Malcolm Moore, Geoffrey Liu, Ronald L Burkes, Christine Brezden-Masley, Michael H Roehrl, Kenneth J Craddock, Ming-Sound Tsao, Tong Zhang, Celeste Yu, Suzanne Kamel-Reid, Lillian L Siu, Philippe L Bedard, Eric X Chen
BACKGROUND: Molecular aberrations in KRAS, NRAS, BRAF, and PIK3CA have been well-described in advanced colorectal cancer. The incidences of other mutations are less known. We report results of molecular profiling of advanced colorectal cancer in an academic cancer center. PATIENTS AND METHODS: Patients with advanced colorectal were enrolled in an institution-wide molecular profiling program. Profiling was performed on formalin-fixed paraffin embedded archival tissues using a customized MassArray panel (23 genes, 279 mutations) or the Illumina MiSeq TruSeq Cancer Panel (48 genes, 212 amplicons, ≥ 500× coverage) in a Clinical Laboratory Improvement Amendments-certified laboratory...
October 23, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29128267/clinical-relevance-of-alternative-endpoints-in-colorectal-cancer-first-line-therapy-with-bevacizumab-a-retrospective-study
#17
Anthony Turpin, Sophie Paget-Bailly, Anne Ploquin, Antoine Hollebecque, Charlotte Peugniez, Farid El-Hajbi, Franck Bonnetain, Mohamed Hebbar
BACKGROUND: We studied the relationship between intermediate criteria and overall survival (OS) in metastatic colorectal cancer (mCRC) patients who received first-line chemotherapy with bevacizumab. PATIENTS AND METHODS: We assessed OS, progression-free survival (PFS), duration of disease control (DDC), the sum of the periods in which the disease did not progress, and the time to failure of strategy (TFS), which was defined as the entire period before the introduction of a second-line treatment...
October 19, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29113730/conversion-to-resection-in-patients-receiving-systemic-chemotherapy-for-unresectable-and-or-metastatic-colorectal-cancer-predictive-factors-and-prognosis
#18
Hiroaki Nozawa, Soichiro Ishihara, Kazushige Kawai, Keisuke Hata, Tomomichi Kiyomatsu, Toshiaki Tanaka, Takeshi Nishikawa, Kensuke Otani, Koji Yasuda, Kazuhito Sasaki, Manabu Kaneko, Koji Murono
BACKGROUND: Systemic chemotherapy increases the possibility of resection in patients with initially unresectable colorectal cancer (CRC), especially patients with hepatic metastasis. However, the predictive factors and prognosis of conversion to resection after chemotherapy in patients with various organ metastases remain largely unknown. PATIENTS AND METHODS: We reviewed the data from metastatic CRC (mCRC) patients who had received oxaliplatin- or irinotecan-based systemic chemotherapy from 2005 to 2016...
October 19, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29169974/a-prospective-multicenter-phase-ii-study-of-the-efficacy-and-feasibility-of-15-minute-panitumumab-infusion-plus-irinotecan-for-oxaliplatin-and-irinotecan-refractory-kras-wild-type-metastatic-colorectal-cancer-short-infusion-of-panitumumab-trial
#19
Kohei Akiyoshi, Tetsuya Hamaguchi, Kenichi Yoshimura, Naoki Takahashi, Yoshitaka Honma, Satoru Iwasa, Atsuo Takashima, Ken Kato, Yasuhide Yamada, Hisashi Onodera, Shigeyuki Takeshita, Hisateru Yasui, Gen Sakai, Sotaro Akatsuka, Kohei Ogawa, Yosuke Horita, Yushi Nagai, Yasuhiro Shimada
BACKGROUND: In some recently updated clinical guidelines, the fully humanized monoclonal antibody panitumumab, combined with irinotecan, has been recommended as an optional third-line chemotherapy for KRAS wild-type metastatic colorectal cancer (mCRC). The present prospective, multicenter phase II study evaluated the effectiveness and safety of short 15-minute panitumumab infusions. PATIENTS AND METHODS: From January 2011 to December 2011, patients with KRAS wild-type mCRC were enrolled at 8 centers...
October 16, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29129559/treatment-and-survival-outcome-of-braf-mutated-metastatic-colorectal-cancer-a-retrospective-matched-case-control-study
#20
Hamzeh Kayhanian, Emily Goode, Francesco Sclafani, Joo Ern Ang, Marco Gerlinger, David Gonzalez de Castro, Scott Shepherd, Clare Peckitt, Sheela Rao, David Watkins, Ian Chau, David Cunningham, Naureen Starling
BACKGROUND: Somatic v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation, present in approximately 10% of metastatic colorectal cancer (mCRC) cases, is associated with poor prognosis. Patient outcome outside of clinical trials has only been reported in small series. We report real-world data on treatment and survival for BRAF-mutated (MT) patients at a single tertiary center, compared with a matched BRAF wild type (WT) control group. PATIENTS AND METHODS: All colorectal cancer patients tested for BRAF mutation, from October 2010 to November 2014 were identified...
October 16, 2017: Clinical Colorectal Cancer
journal
journal
39741
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"